Disulfiram and copper combination therapy targets NPL4, cancer stem cells and extends survival in a medulloblastoma model.

<h4>Background</h4>Medulloblastoma (MB) is the most common brain malignancy in children, and is still responsible for significant mortality and morbidity. The aim of this study was to assess the safety and efficacy of Disulfiram (DSF), an FDA-approved inhibitor of Aldehyde-Dehydrogenase...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Riccardo Serra, Tianna Zhao, Sakibul Huq, Noah Leviton Gorelick, Joshua Casaos, Arba Cecia, Antonella Mangraviti, Charles Eberhart, Renyuan Bai, Alessandro Olivi, Henry Brem, Eric M Jackson, Betty Tyler
Formato: article
Lenguaje:EN
Publicado: Public Library of Science (PLoS) 2021
Materias:
R
Q
Acceso en línea:https://doaj.org/article/e05e4fd3bbde45adb82280054e4266fb
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!